Crossmark

Use of ustekinumab as the treatment of choice in patient with corticodependent immune-mediated colitis secondary to pembrolizumab

Crossref DOI link: https://doi.org/10.1016/j.gastre.2025.502469

Published Print: 2025-12

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

García Martínez, Alejandro

Gallego Gallegos, María Regla
License Information

Text and Data Mining valid from 2025-12-01

Text and Data Mining valid from 2025-12-01

stm-asf valid from 2025-12-01

stm-asf valid from 2025-12-01

stm-asf valid from 2025-12-01

stm-asf valid from 2025-12-01

stm-asf valid from 2025-12-01
More Information

This article is maintained by: Elsevier

Article Title: Use of ustekinumab as the treatment of choice in patient with corticodependent immune-mediated colitis secondary to pembrolizumab

Journal Title: Gastroenterología y Hepatología (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.gastre.2025.502469

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.gastrohep.2025.502469

Content Type: article

Copyright: © 2025 Elsevier España, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.